Altrinsic Global Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

Altrinsic Global Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,625	Closed	-$845K	–	88
2016 Q4	$845K	Hold	8,625	–	–	0.03%	76
2016 Q3	$857K	Hold	8,625	–	–	0.03%	74
2016 Q2	$1.06M	Hold	8,625	–	–	0.03%	73
2016 Q1	$1.1M	Sell	8,625 -2,000	-19%	-$162K	0.03%	74
2015 Q4	$491K	Hold	10,625	–	–	0.01%	82
2015 Q3	$1.02M	Hold	10,625	–	–	0.02%	76
2015 Q2	$1.46M	Sell	10,625 -328	-3%	-$52.4K	0.03%	79
2015 Q1	$1.95M	Sell	10,953 -875	-7%	-$152K	0.04%	74
2014 Q4	$2.37M	Sell	11,828 -672	-5%	-$121K	0.05%	67
2014 Q3	$2.52M	Hold	12,500	–	–	0.05%	70
2014 Q2	$2.01M	Hold	12,500	–	–	0.04%	73
2014 Q1	$2.5M	Buy	+12,500	New	+$2.5M	0.04%	74

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Altrinsic Global Advisors's ARGS Position: Q1 2017 in Review

Altrinsic Global Advisors sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 8,625 shares — an estimated $845K sold.

Altrinsic Global Advisors first reported a position in ARGS in Q1 2014 and held it in 12 quarters. The position peaked at $2.52M in Q3 2014. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

Altrinsic Global Advisors reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Altrinsic Global Advisors sold 8,625 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $845K.
Altrinsic Global Advisors first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 12 quarters.
Altrinsic Global Advisors's Argos Therapeutics, Inc. position peaked at $2.52M in Q3 2014.
43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on Altrinsic Global Advisors's 13F filing for Q1 2017, filed 15 May 2017.